Reference | Sample | sEV isolation | Normalization | ncRNA (expression in PC) | Patients enrolled | Diagnostic accuracy (AUC) (PC vs. non-PC if not stated otherwise) | |
---|---|---|---|---|---|---|---|
(↑) | (↓) | ||||||
Que et al. [142] | Serum | UC | RNU6B | miR-17-5p miR-21 | – | 22 PDAC, 6 BPT, 7 AC, 6 CP, 8 HC | 0.887 (miR-17-5p) 0.897 (miR-21) |
Madhavan et al. [156] | Serum | DGUC | RNU6, SNORD43 18S & 5S rRNA | miRs 1246, 4644, 3976, 4306 | – | 112 PDAC, 11 other PC, 22 BPT, 23 CP, 18 HC | Not assessed |
Machida et al. [158] | Saliva | TEI | RNU6 | miR-1246 miR-4644 | – | 12 PBC (thereof 9 PDAC), 13 HC | 0.814 (miR-1246), 0.763 (miR-4644) 0.833 (miRs 1246 + 4644) |
Lai et al. [146] | Plasma | UC | miR-425-5p | miRs 10b, 20a, 21, 30c, 106b, 181a | miRs let7a, 122 | 29 PDAC, 11 CP, 6 HC | 1.00 (miRs 10b, 21, 30c, 181a, let7a) 0.99 (miR-122), 0.95 (miR-20a), 0.85 (miR-106b) |
Chen et al. [229] | Serum | UC | 5S rRNA | miR-23b-3p | – | 16 PDAC, 20 HC | 1.00 (miR-23-3p) |
Xu et al. [157] | Plasma | EQ | cel-miR-54 | miR-1246 miR-196a miR-196b (n.s.) | – | 15 PC (UICC I-IIa) 15 HC | 0.73 (miR-1246) 0.81 (miR-196a) 0.71 (miR-196b) |
Goto et al. [145] | Serum | EQ | not specified | miRs 21, 191, 451a | – | 32 PC, 22 HC | 0.826 (miR-21), 0.788 (miR-191) 0.759 (miR-451a) |
Zhou et al. [152] | Plasma | EQ | miR-103a | miR-122-5p, miR-193b-3p | miR-221-3p | 31 PC, 37 HC | 0.772 (miR-122-5p), 0.651 (miR-193b-3p) 0.849 (miRs 122-5p + 193b-3p) |
Kitagawa et al. [162] | Plasma | not specified | not specified | SNORA74A, SNORA25, SNORA22, SNORA14B, SNORD22 | – | 27 PDAC, 13 HC | 0.909 (SNORA74A) 0.903 (SNORA25) 0.883 (SNORA22) 0.875 (SNORA14B) 0.862 (SNORD22) |
Nakamura et al. [160] | PJ | UC | miR-16 | miR-21 miR-155 | – | 27 PDAC, 8 CP | 0.83 (miR-21) 0.89 (miR-155) 0.91 (miR-21 + miR-155) |
Zou et al. [230] | Serum | EQ | cel-miR-39 | miRs 19a, 19b, 192 | – | 32 PC, 32 HC | Not assessed |
Shang et al. [204] | Plasma | UC | RNU6 | – | miR-1231 | 32 PC, 20 HC | Not assessed |
Sun et al. [76] | Plasma | UC | not specified | miR-3607-3p | – | 40 PC, 20 HC | Not assessed |
Takahashi et al. [55] | Serum | EQ | RNU6B | lncHULC | – | 20 PDAC, 22 IPMN, 21 HC | 0.92 |
Reese et al. [155] | Serum | UC | cel-miR-39 | miRs 200b, 200c | – | 56 PDAC, 11 CP, 22 HC | 0.77 (miR-200b TSE) 0.68 (miR-200c TSE) 0.97 (4-miR-panel + CA.19-9) |
Pu et al. [151] | Plasma | TEI | n/a * | miR-10b, miR-21 | – | 36 PC, 65 HC | 0.6543 (miR-10b) 0.7171 (miR-21) 0.791 (miR-10b + miR-21) |
Yoshizawa et al. [159] | Urine | EQ | miR-8069 | ratio of miRs 3940-5p/8069 | – | 43 PDAC, 12 CP, 25 HC | 0.732 |
Yang et al. [167] | Plasma | TENPO | not specified | miR-409 | – | 57 PDAC, 49 HC, 12 CP, 3 IPMN, 12 BPT, 3 others | 0.95 (5-marker-panel including miR-409, 2 mRNAs, ccfDNA, and CA.19-9) |
Flammang et al. [231] | Serum | UC | cel-miR-39 | miR-192-5p | – | 44 PDAC, 11 CP, 12 HC | 0.83 (PDAC vs. HC) 0.54 (PDAC vs. CP) |
Wu et al. [144] | Serum | EQ | cel-miR-39 | miR-21, miR-210 | – | 30 PC, 10 CP | 0.83 (miR-21), 0.85 (miR-210) 0.90 (miR-21 + miR-210) 0.9 (miR-21 + CA-19-9) 0.9 (miR-210 + CA.19.9) |
Guo et al. [116] | Serum | EQ | β-actin | lncUCA1 | – | 46 PC, 16 HC | 0.7813 |
Zhou et al. [150] | Plasma | MC | CD81 | miRs 10b, 21, 451a | – | 30 PC, 10 CP | 0.875 (miR-10b) 0.939 (miR-21) 0.930 (miR-451a) 1.00 (miRs 10b + 21 + 451a + EphA2) |
Cao et al. [107] | Plasma | TEI | cel-miR-39 | miR-616 miR-4465 | – | 50 PC, 30 HC | Not assessed |
Wang et al. [232] | Serum | EEM | RNU6B | – | miR-1226 | 17 PDAC, 12 BPD | 0.74 (PDAC vs. BPD) |
Shao et al. [154] | Serum | EQ | cel-miR-39 | miR-483-3p | – | 63 PDAC, 22 HC | 0.69 (sEV miR-483-3p) 0.84 (serum + sEV miR-483-3p) |
Han et al. [115] | Plasma | EQ | RNU6 | lncCCAT1 | – | 93 PC, 93 HC | not assessed |